PTEN alterations have been associated with a worse prognosis in patients with advanced prostate cancer. The ability to accurately identify and interpret these alterations offers the potential to tailor treatments more effectively and improve patient outcomes.
Location
New York, New York, USA
By the numbers
23 years of experience in medical oncology
46 clinical trials led as Principal Investigator at MSK
112 peer-reviewed publications focused on prostate cancer
PTEN alterations have been associated with a worse prognosis in patients with advanced prostate cancer. The ability to accurately identify and interpret these alterations offers the potential to tailor treatments more effectively and improve patient outcomes.
About Dr Dana Rathkopf
Dr Dana Rathkopf is an Attending Physician at Memorial Sloan Kettering Cancer Center (MSK) in New York City and a Professor of Clinical Medicine at Weill Cornell Medical College. She is a genitourinary (GU) medical oncologist who specializes in the treatment of advanced and high-risk prostate cancer.
At MSK, Dr Rathkopf serves as Deputy Associate Director, Clinical Research Administration, and Chair of the Research Council, overseeing the scientific merit and progress of patient-centered research. She is also the site principal investigator for the Department of Defense Prostate Cancer Clinical Trials Consortium, a national initiative aimed at expanding access to innovative clinical trials.
Dr Rathkopf has led multiple investigator-initiated trials targeting the phosphoinositide 3-kinase (PI3K) pathway, both as monotherapy and in combination with other agents, for the treatment of advanced prostate cancer. Her research has contributed to pivotal studies that have shaped the standard of care in metastatic prostate cancer. She has received multiple honors for her work, including recognition as one of America’s Top Doctors and Exceptional Women in Medicine by Castle Connolly.
Key areas of interest
- Translating clinical trial insights into practice guidelines
- Targeting the androgen receptor and PI3K pathways in advanced prostate cancer
- Improving access to clinical trials for patients
Explore key pages
AKT, protein kinase B; mHSPC, metastatic hormone-sensitive prostate cancer; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog.
